ROBERTET: A SOLID FIRST HALF 2026

Robertet reported H1 2026 revenue of €444.3 million, down 0.5% reported but up 2.8% organically, while recurring EBITDA declined 6.6% to €93.6 million and margin contracted 140bps to 21.1%. Net income fell 7.4% to €54.2 million as investments in capacity, teams and systems increased depreciation and operating costs. Strong Fragrances organic growth of 12.6%, Health & Beauty growth of 11.3%, and expansion in South America (+21%) and Asia (+12%) partly offset weaker Raw Materials (-5.5%) and Flavors (-1.7%); management targets 3%-5% FY2026 organic growth despite limited visibility.

Analysis

The investable issue is not the modest growth outlook but the quality of incremental revenue: mix is shifting toward higher-value fragrance and beauty applications while two historically material, more cyclical inputs/end-markets are contracting. That can protect gross margin over time, but current operating leverage is negative because capacity, commercial and systems spending is being recognized ahead of utilization. For RBT, the next 1-3 months hinge on whether management can quantify payback periods and confirm that second-half growth accelerates without another step-down in EBITDA margin.

Currency is the more immediate earnings risk than demand: the gap between constant-currency and reported growth implies overseas expansion is not translating cleanly into euro results. A further EUR appreciation would make the full-year organic target insufficient to support consensus reported-sales estimates, particularly given the company’s high international exposure. Improving leverage is a partial offset, but it does not repair an operating-margin miss; the key call question is whether pricing and procurement can hold gross margin while new facilities ramp.

Competitively, the growth of independent premium fragrance brands favors agile, vertically integrated naturals suppliers over scale-led peers such as Givaudan (GIVN), dsm-firmenich (DSFIR) and Symrise (SY1), whose portfolios have greater exposure to broad-based flavors and large consumer-staples customers. The contrarian view is that investors may be pricing the investment phase as discretionary margin dilution rather than a capacity constraint being relieved ahead of emerging-market demand. That thesis fails if fragrance growth normalizes sharply or if Raw Materials and Flavors remain negative into 2027, leaving fixed-cost absorption structurally impaired.

RBT's concentrated family control and relatively limited liquidity argue against treating this as a short-term beta trade. The September 18 call is a catalyst for estimate revisions, but a durable rerating requires evidence over 6-18 months that capex converts into revenue faster than depreciation and working-capital needs consume cash.

Key Decisions for Investors

• Maintain a neutral RBT stance into the earnings call; add only if management reiterates the full-year growth range and provides a credible second-half margin bridge showing stabilization versus the first-half run rate. Falsifier: another EBITDA-margin decline in H2 despite higher organic growth.
• For a 6-12 month relative-value expression, monitor long RBT / short SY1 or DSFIR only after confirming fragrance-led growth is sustained and RBT’s order intake is accelerating. The rationale is premium-naturals and emerging-market mix versus broader flavor exposure; avoid execution until valuation, borrow and liquidity data are verified.
• Set an FX sensitivity alert: if EUR/USD or the relevant emerging-market currency basket appreciates enough to create another roughly 3% reported-sales translation headwind, reduce reported-revenue expectations regardless of organic performance. This is the clearest near-term risk to an otherwise intact operating narrative.
• Request on the call: capex by project, expected utilization timeline, price/cost balance, and whether working-capital intensity rises with Latin America/Asia growth. Without these disclosures, treat the 2030 investment-return claim as unverified rather than a basis for multiple expansion.